The top 100 enterprises of over-the-counter drugs announced, whose are the top three

[pharmaceutical network industry trends] with the impact of a series of policies on prescription drugs, many pharmaceutical companies began to pay more attention to prescription drugs, and strengthen the product promotion and layout in the retail market outside the hospital According to the data, according to the average retail price of the terminal, the sales scale of China's physical drugstores and online drugstores (including drugs and non drugs) reached 610.6 billion yuan in 2018, up 10.1% year on year The development trend of continuous growth has also enabled more pharmaceutical enterprises to join in the competition for over-the-counter drug market Recently, the China over the counter drug association released the "comprehensive statistical ranking of China's over-the-counter drug manufacturers in 2019", with 100 pharmaceutical companies on the list Among them, China Resources 39, Taiji group and revisionpharma ranked in the top three It is reported that the statistical survey of OTC enterprises and product brands in 2019 is the sales volume of OTC drugs calculated based on the factory price including tax in 2018, and the enterprises and products not involved in the declaration are not listed in the announcement Next, I will take you to understand the top three enterprises According to its 2019 half year report, from January to June, Cr Sanjiu achieved an operating revenue of 7.167 billion yuan, up 10.73% year on year, including 3.695 billion yuan for self diagnosis and treatment business (mainly non prescription drugs), 11.97% year on year, and 3.102 billion yuan for prescription drugs business, up 9.01% year on year At present, its self diagnosis and treatment business has covered more than 400000 pharmacies across the country, and is constantly expanding the coverage of terminals CR Sanjiu will continue to explore new models in the marketing and brand building of over-the-counter drugs, and continue to strengthen cooperation with large pharmaceutical e-commerce platforms such as Jingdong pharmacy and Ali health pharmacy   It is reported that CR Sanjiu started with OTC (over-the-counter medicine) business in the early stage In the past two years, it has upgraded its positioning from traditional OTC to self diagnosis and treatment On the basis of the original three traditional categories of cold, skin and stomach, it has introduced Gynecology, liver disease and other specialized categories, and extended them to such big health fields as dietary nutrition supplements and traditional Chinese medicine tonic, trying to build a "full range of family medicine" ”Product group Among them, the sales scale of cold series has exceeded 2 billion yuan, becoming the core category of self diagnosis and treatment Taiji group data shows that in the first half of 2019, Taiji Group's operating revenue was 6.149 billion yuan, an increase of 19.51% over the same period of last year; the net profit attributable to shareholders of listed companies was 89.1041 million yuan, an increase of 64.07% over the same period of last year; the net profit attributable to shareholders of listed companies after deducting non economic profit and loss was 53.6261 million yuan, an increase of 2.56% over the same period of last year In the first half of the year, the total sales expense was 1.7 billion yuan, including 916 million for market maintenance and development, which was 19.62 times of the net profit attributable to the shareholders of the listed company In addition, the data also shows that Taiji Group products take digestive system drugs, respiratory system drugs and cardiovascular and cerebrovascular drugs as three strategic product lines In the first half of the year, the gross profit margin of digestive system products, respiratory system products and cardiovascular and cerebrovascular products was 47.84%, 50.87% and 67.54%, respectively   In last year's "2018 China's over-the-counter drug products" comprehensive statistical ranking (Chinese patent medicine), Taiji Group Huoxiang Zhengqi liquid won the top of the "cold and heat dampness OTC brand", nasosinusitis oral liquid won the top of the "five senses OTC products", Jizhi syrup won the second place of "cough, phlegm and asthma relief OTC brand", and Tongtian oral liquid won the "headache and insomnia OTC brand" season Army As a well-developed pharmaceutical enterprise, revisionpharma has three well-known brands of "revisionpharma, Tongyao and stashu", as well as 14 systematic sales platforms The brand advantages and mature sales system established in the early stage ensure the sustainable operation advantages of the pharmaceutical industry in OTC fields such as stomach medicine   According to the public data, in 2014, the revised pharmaceutical industry ranked 50th among the private enterprises with a revenue of 50.7 billion yuan, ranking first among the private pharmaceutical industry; in 2015, the revised output value was 58.8 billion yuan, and the sales revenue was 57.5 billion yuan, achieving a growth rate of 16%, ranking 53rd among the top 500 private enterprises, still maintaining the leading position in the pharmaceutical industry; however, in 2016, the revised pharmaceutical industry fell to the pharmaceutical industry Second in the industry, sales revenue reached about 63.6 billion yuan, with growth rate down to 8.16% In 2017, the decline accelerated, and the corrected total operating revenue only increased by less than 200 million yuan, about 63.8 billion yuan, with a growth rate of only 0.31% It is understood that in the future, the goal of revising the pharmaceutical industry is to strive to achieve the sales revenue target of 100 billion yuan in 10 years, reach the target of trillion yuan by 2030, and become one of the top 100 pharmaceutical enterprises in the world.